# MedTech Entrepreneurs Management

MedTech Entrepreneurs Management is a Private Equity based in Graefelfing, Germany.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Graefelfing, Germany
- **Region:** Europe
- **Address:** Schulstr. 47, 82166 Graefelfing, Germany
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** www.mte.vc
- **LinkedIn:** https://linkedin.com/company/mte-medtech-entrepreneurs

## Regulatory record

- **Reports private funds:** No

## About

MedTech Entrepreneurs Management is a private equity firm based in Munich, Germany. It focuses on a Venture Capital strategy. The firm has a team of three staff, including three investment professionals.

## Sectors

- MedTech
- Digital Health

## People

- Dominik Moll — Managing Partner
- Dr. Andreas Lindner — Venture Partner
- Dr. Jörg Muschiol — Venture Partner
- Carl Härtlein — Venture Partner
- Dr. Franz MJ Pfister — Venture Partner

## Questions

### Who runs investment decisions at MedTech Entrepreneurs Management?

Managing Partner Dominik Moll leads the firm. He draws on two decades of executive roles at Johnson & Johnson, Kimberly-Clark, and 3M, plus 15 years as a c-level shareholder in MedTech SMEs. The firm lists four additional venture partners — Dr. Andreas Lindner, Dr. Jörg Muschiol, Carl Härtlein, and Dr. Franz MJ Pfister — who contribute deal-sourcing, clinical, and operational expertise, but ultimate investment authority rests with the managing partner and the investment committee.

### How does MTE source proprietary deal flow?

MTE sources predominantly from academically rooted MedTech founders across Germany, Austria, and Switzerland, leveraging the managing partner's management-due-diligence background and the venture partners' hospital and clinical-trial networks. The firm deploys a 'cooperative milestone management' model that embeds operating partners into corporate governance and reimbursement strategy early, which attracts founders needing regulatory pathway support before larger VCs engage.

### Does MTE participate in fund commitments or only direct deals?

MTE makes direct early-stage equity investments into medical-device and digital-health startups, with initial tickets from €500,000 to €3 million. It does not publish information about participating in other fund commitments as a limited partner.

### What investment stages does MTE typically target?

The firm explicitly targets pre-seed and early-stage rounds, characterizing itself as a bridge between angel investors and larger venture-capital funds. It enters before syndicates are fully formed, often as the first institutional check, and works with founders to achieve milestones that de-risk later-stage investment.

### Which sectors does MTE explicitly avoid?

The firm states clearly on its website that it does not invest in pharmaceutical or biotechnology companies. Its mandate covers medical devices (Class I through III), Digital Health Applications (DiGA), and hygiene and infection-prevention technologies but excludes drug development and biotech platforms.

### What is MTE's posture on reimbursement strategy as an investment criterion?

MTE treats prospective NUB/DRG/DiGAV reimbursement status as a central investment criterion. The firm cites data showing 97% of startups fail to secure new reimbursement codes in Germany and incorporates reimbursement-application planning into its milestone-based operational support for portfolio companies, using this as both a risk-mitigation lever and a value-creation thesis.

## Related profiles

- [MedScience Ventures](https://altss.com/profile/medscience-ventures)
- [MedTex Ventures](https://altss.com/profile/medtex-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/medtech-entrepreneurs-management

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology